B. I. Eriksson (1), O. E. Dahl (2), M. H. Huo (3), A. A. Kurth (4), S. Hantel (5), K. Hermansson (6), J. M. Schnee (7), R. J. Friedman (8), for the RE-NOVATE II Study Group
(1) University of Gothenburg, Department of Orthopaedics, Sahlgrenska University Hospital, Mölndal, Sweden; (2) Elverum Central Hospital, Norway; (3) Department of Orthopedic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA; (4) Department of Orthopaedic Surgery, University Medical Centre, Mainz, Germany; (5) Medical Data Services, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; (6) Medical Department, Boehringer Ingelheim AB, Stockholm, Sweden; (7) Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA; (8) Medical University of South Carolina and Charleston Orthopaedic Associates, Charleston, South Carolina, USA
This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embolism) plus VTE-related death. The main safety outcome was major bleeding. In total, 2,013 were treated, of whom 1,577 operated patients were included in the primary efficacy analysis. The primary efficacy outcome occurred in 7.7% of the dabigatran group versus 8.8% of the enoxaparin group, risk difference (RD) –1.1% (95%CI –3.8 to 1.6%); p<0.0001 for the pre-specified non-inferiority margin. Major VTE plus VTE-related death occurred in 2.2% of the dabigatran group versus 4.2% of the enoxaparin group, RD –1.9% (-3.6% to –0.2%); p=0.03. Major bleeding occurred in 1.4% of the dabigatran group and 0.9% of the enoxaparin group (p=0.40). The incidence of adverse events, including liver enzyme elevations and cardiac events, during treatment was similar between the groups. Extended prophylaxis with oral dabigatran 220 mg once-daily was as effective as subcutaneous enoxaparin 40 mg once-daily in reducing the risk of VTE after total hip arthroplasty, and superior to enoxaparin for reducing the risk of major VTE. The risk of bleeding and safety profiles were similar.
venous thromboembolism, prophylaxis, oral anticoagulant, dabigatran etexilate, Total hip arthroplasty
D. Bergqvist (1), J. I. Arcelus (2), P. Felicissimo (3), ETHOS investigators
Thromb Haemost 2012 107 2: 270-279
Manuel Monreal1, Luis Peidro2, Carlos Resines3, Carlos Garcés4, José Luís Fernández5, Eduardo Garagorri6, Juan Carlos González7, for the NETCOT Investigators*
Thromb Haemost 2008 99 6: 1112-1115
arthritis + rheuma 2007 27 6: 345-350
Atherosclerosis is an inflammatory and thrombotic disease, in which both CD4+ T cells and...
The May 2013 issue of Thrombosis and Haemostasis 109.5 is a clinically relevant 'state of the art'...
Starting with the April 2013 issue of "Thrombosis and Haemostasis" TH109.4, the ESC...